These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20939648)

  • 21. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
    Henderson DC; Copeland PM; Borba CP; Daley TB; Nguyen DD; Cagliero E; Evins AE; Zhang H; Hayden DL; Freudenreich O; Cather C; Schoenfeld DA; Goff DC
    J Clin Psychiatry; 2006 May; 67(5):789-97. PubMed ID: 16841629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A crossover study on lipid and weight changes associated with olanzapine and risperidone.
    Su KP; Wu PL; Pariante CM
    Psychopharmacology (Berl); 2005 Dec; 183(3):383-6. PubMed ID: 16240162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
    Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
    Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
    Henderson DC; Fan X; Sharma B; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
    J Psychiatr Pract; 2009 Jul; 15(4):251-61. PubMed ID: 19625881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
    Wyszogrodzka-Kucharska A; Kunert-Radek J; Rabe-Jabłońska J
    Psychiatr Pol; 2005; 39(6):1143-55. PubMed ID: 16526181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
    Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
    Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
    Yasui-Furukori N; Furukori H; Sugawara N; Tsuchimine S; Fujii A; Inoue Y; Kaneko S
    Hum Psychopharmacol; 2010 Apr; 25(3):236-42. PubMed ID: 20373475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The lipid metabolism abnormality in patients administered with olanzapine].
    Amano T; Hosaka S; Takami H; Sugiyama C; Oda K; Morikawa R
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):257-61. PubMed ID: 23373312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study.
    Chen Q; Cai ZJ; Mao PX; Zhai YM; Mitchell PB; Tang YL
    J Psychiatr Res; 2008 Dec; 43(2):124-8. PubMed ID: 18423490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
    Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
    Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.
    Konarzewska B; Wołczyński S; Szulc A; Galińska B; Popławska R; Waszkiewicz N
    Psychoneuroendocrinology; 2009 Jan; 34(1):129-39. PubMed ID: 18838228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.